Changeflow GovPing Healthcare & Life Sciences US20260109748A1 - Plasmacytoid Dendritic Cell B...
Routine Consultation Added Final

US20260109748A1 - Plasmacytoid Dendritic Cell Binding Agents

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO published application US20260109748A1, filed August 13, 2025, disclosing chimeric proteins and protein complexes that bind plasmacytoid dendritic cells (pDC), including Clec4C targets. Invented by Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, and Erik DEPLA, the disclosed agents and pharmaceutical compositions are proposed for diagnostic and therapeutic applications, including treatment of autoimmune diseases. The application has been published for examination but has not yet been granted.

“The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.

What changed

The USPTO published patent application US20260109748A1 covering agents, chimeric proteins, and chimeric protein complexes that bind plasmacytoid dendritic cells (pDC), specifically targeting Clec4C. The application discloses pharmaceutical compositions containing these binding agents and their use in diagnostic and therapeutic methods, including treatment of autoimmune diseases.

Pharmaceutical and biotechnology companies developing immunotherapy platforms, autoimmune disease treatments, or dendritic cell-based diagnostics should monitor this application's prosecution. While a published application does not create enforceable patent rights, it establishes prior art that could affect freedom-to-operate analyses for competing therapeutic or diagnostic products targeting pDCs.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MODULATION OF DENDRITIC CELL LINEAGES

Application US20260109748A1 Kind: A1 Apr 23, 2026

Inventors

Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, Erik DEPLA

Abstract

The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present Invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.

CPC Classifications

C07K 14/56 A61P 35/00 C07K 14/565 C07K 16/2815 C07K 16/2818 C07K 16/2827 C07K 16/2851 C07K 16/2896 A61K 38/00 A61K 2039/505 C07K 2317/22 C07K 2317/31 C07K 2317/569 C07K 2317/71 C07K 2317/73 C07K 2317/76 C07K 2319/30 C07K 2319/33 C07K 2319/74

Filing Date

2025-08-13

Application No.

19298570

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Consultation
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent application filing Biotherapeutic research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!